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Introduction 
Malignancies that arise in the cells of the hematopoietic system
are as varied as the individual lineages that comprise this tis-
sue, and can be broadly categorized into acute and chronic
leukemias, myelodysplastic and myeloproliferative syndromes,
Hodgkin’s disease, and the non-Hodgkin’s lymphomas. As a
result of advances in understanding of both normal hematopoi-
etic development and the molecular pathology of hematopoietic
malignancies, significant improvements have occurred in our
ability to accurately diagnose, subclassify, and treat these can-
cers. True treatment successes can be claimed for many of the
pediatric acute leukemias and lymphomas (Pui et al., 2001;
Weitzman et al., 2002), and for acute promyelocytic leukemia, a
specific subtype of acute myeloid leukemia (AML) seen in both
the pediatric and adult populations (Warrell, 1996). However,
significantly fewer successes have occurred in the treatment of
adult patients with hematopoietic malignancies. Moreover, as
the frequencies of several of the more common cancer sub-
types have steadily decreased during the last two decades, the
overall frequency of hematopoietic malignancies has increased,
primarily due to increases in the frequency of non-Hodgkin’s
lymphomas and myeloid leukemias in the adult population
(http://www.seer.cancer.gov).
The differences in treatment successes between pediatric
and adult hematopoietic malignancies are likely to involve a
combination of factors including disease biology, host features,
and treatment strategies (Gilliland and Tallman, 2002). One of
the most striking aspects of hematopoietic malignancies is the
marked difference in the frequency of specific subtypes as a
function of age. Although the total number of hematopoietic
neoplasms in adults far exceeds the number seen in children, in
the pediatric and adolescent population, these malignancies
comprise almost 50% of all cancers, whereas in adults, they
comprise only 5%–8% (http://www.seer.cancer.gov). In addi-
tion, the spectrum of hematopoietic malignancies varies signifi-
cantly between pediatric and adult patients (Figure 1). Acute
lymphoblastic leukemia (ALL) is the most common cancer seen
in the pediatric population and accounts for greater than 50% of
hematopoietic malignancies in this age group. By contrast, ALL
is a relatively rare leukemia subtype in adults, accounting for
only 2%–3% of hematopoietic malignancies. Similarly, in chil-
dren and adolescents, T cell non-Hodgkin’s lymphomas (NHLs)
are nearly equal in number to those of B cell lineage, whereas in
adult patients, B cell NHLs predominate. In addition, in pediatric
patients, certain NHL subtypes occur at a high frequency,
including Burkitt’s and anaplastic large cell lymphoma, whereas
in adults the follicular lymphomas predominate, a NHL subtype
that is exceedingly rare in pediatric patients. Also, B cell chronic
lymphocytic leukemia and multiple myeloma occur almost
exclusively in adult patients. Lastly, major differences exist in the
overall frequency and subtypes of AML and related myelodys-
plastic syndromes (MDS), with the incidence of these diseases
rising linearly after the age of 40.
The underlying causes for the variation in disease spectrum
between pediatric and adult patients are likely to include differ-
ences in the stem cell population that are targeted by mutations,
the number and type of mutations necessary to induce a fully
malignant phenotype, and the internal homeostatic environ-
ment of a developing host as compared to that of a fully mature
one. The predominance of ALL in pediatric patients may reflect
a combination of the existence of a susceptible stem cell popu-
lation during early and mid-development, and the requirement
for only a limited number of mutations in these cells to induce
overt disease. Similarly, the low frequency of MDS-related AML
in pediatric patients could be secondary to a need for multiple
genetic alterations to induce this type of AML.
What lessons can we learn from our expanding knowledge
of the underlying molecular pathology of pediatric leukemias
and lymphomas, and from the successes we have achieved in
their treatment? More importantly, can these lessons lead to
future improvements in cure rates for the larger number of adult
patients with leukemia and lymphoma? In this article, we focus
on the specific aspects of pediatric leukemias that may shed
light on some of the acute leukemias seen in adults.
ALL—Differences in both biology and treatment
The major genetic subtypes of pediatric and adult ALL are listed
in Table 1. The range of oncogenic mechanisms is similar in the
two age groups, and includes enhanced expression of proto-
oncogenes (MYC, TAL1, LYL1, and HOX11), the expression of
translocation-generated fusion oncogenes (BCR-ABL, TEL-
AML1, E2A-PBX1, and MLL fusions), and alterations in chro-
mosome number including increases and decreases. Studies in
a variety of experimental systems have demonstrated that the
majority of these lesions are insufficient on their own to gener-
ate a full leukemic phenotype (Adams et al., 1985; Hawley et al.,
1994; Andreasson et al., 2001; Smith et al., 1999, 2002; Corral
et al., 1996). The number and nature of cooperating mutations
required to induce a full leukemic phenotype appears to vary
depending on the initiating lesions. The early age of disease
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onset in many children with ALL, and the high rate of disease
concordance in monozygotic twins, suggest that some of the
initiating lesions are acquired in utero. Indeed, an innovative
series of “back-tracking” experiments demonstrated that
leukemia-specific translocation breakpoints can be detected in
neonatal blood specimens from most children who are diag-
nosed with ALL during the first decade of life (Ford et al., 1993,
1998; Wiemels et al., 1999). Furthermore, twins that were con-
cordant for the development of ALL frequently shared the same
leukemia-associated chromosomal fusion both at birth and
when they presented with ALL (Ford et al., 1998). Although
these data unequivocally demonstrate that leukemia-associat-
ed fusion oncogenes are detectable at birth in many children
who later develop ALL, the overall incidence of these abnormal-
ities is unknown, as is the percentage of infants with in utero
acquired leukemia-associated translocation such as MLL-AF4
or TEL-AML1 that will ultimately develop ALL.
What is the nature of these cooperating mutations in child-
hood ALL, and how are they acquired?
Greaves has proposed a provocative
hypothesis—that lymphoid proliferation
in response to viral illnesses directly or
indirectly provides additional “hits” that
contribute to the development of ALL
(Greaves, 1996). While this idea is con-
sistent with the age-adjusted peak inci-
dence of ALL, there is no direct
evidence that supports it.
With modern chemotherapeutic regimens, approximately
80% of children with ALL are cured (Pui et al., 2001; Gaynon et
al., 2000). This is in marked contrast to adult ALL, where much
lower cure rates are achieved despite the use of myeloablative
regimens with hematopoietic stem cell transplantation in many
patients who enter remission (Thomas et al., 2001; Annino et
al., 2002; Linker et al., 2002). What might explain these dramat-
ic differences? First, many adult patients have unfavorable bio-
logic features at diagnosis. For example, BCR-ABL fusions are
strongly associated with chemoresistant leukemia in all age
groups, but are much more prevalent in adults with ALL than in
pediatric cases (?30% versus <5%, see Table 1) (Radich,
2001). By contrast, leukemias with TEL-AML1 translocations,
which are frequently cured with chemotherapy alone, are more
common in children (Romana et al., 1995; Shurtleff et al., 1995;
McLean et al., 1996). A second factor that may be important
involves the nature of both the susceptible target cell and the
spectrum of cooperating mutations. In particular, the intrauter-
ine origin of pediatric ALL raises the possibility that substantial
functional differences exist between the leukemia-initiating cell
in children and adults, as has been shown for hematopoietic
stem cells derived from umbilical cord blood versus adult bone
marrow (Gluckman, 2000). Furthermore, if viral infections play a
role in the acquisition of cooperating events in pediatric ALL but
not in the corresponding adult leukemias, the spectrum of these
mutations may differ between childhood and adult cases.
Intrinsic differences in either the leukemia-initiating cell or the
nature of secondary mutations that occur in pediatric versus
adult ALL could, in turn, modulate responses to chemothera-
peutic agents.
Differences in the way in which pediatric and adult patients
with ALL are treated is a third possible factor that might influence
cure rates. While limited data address this issue, an intriguing
preliminary report found that adolescents with ALL enrolled on
Children’s Cancer Group protocols had a superior outcome
compared to similar age patients who were treated according to
a concurrent Cancer and Leukemia Group B regimen designed
for adult patients (Stock et al., 2000).These data raise the impor-
Figure 1. Frequency of the major subtypes of
hematopoietic malignancies in pediatric and
adult patients
The pie charts show the relative frequency of
the major hematopoietic malignancies in chil-
dren (0 to 19 years) and adults (>19 years). The
major leukemia and lymphoma subtypes
include chromic myelogenous leukemia (CML),
chromic lymphocytic leukemia (CLL), Hodgkin’s
disease, non-Hodgkin’s lymphoma (NHL), multi-
ple myeloma (MM), acute Lymphoblastic
leukemia (ALL), acute myeloid leukemia (AML),
myelodysplastic syndrome (MDS), and myelo-
proliferative disease (MPD).
Table 1. Acute lymphoblastic leukemia
Leukemia subtype Pediatric Adult
T cell
TAL1 lp32 6% 12%
HOX11L2 5q35 2% 1%
LYL1 19p13 1.5% 2%
HOX11 10q24 0.5% 6%
B cell
Hyperdiploidy > 50 chromosomes 25% 6%
Hypodiploidy < 45 chromosomes 1% 1%
TEL-AML1 t(12;21) 22% 2%
MLL rearrangements (t[4;11], t[11;19], t[9;11], etc.) 8% 10%
E2A-PBX1 t(1;19) 5% 3%
BCR-ABL t(9;22) 3% 30%
MYC t(8;14), t(2;8), t(8;22) 2% 4%
Others 24% 23%
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tant possibility that the higher intensity therapy used by pediatric
oncologist to treat ALL patients may in part be responsible for
the better outcome seen in patients treated on their protocols.
Additional studies will be required to verify this possibility.
A major challenge that remains for both pediatric and adult
ALL is to identify patients at diagnosis or early during treatment
who are destined to relapse, especially since relapsed ALL is
largely refractory to salvage regimens.Two complementary tech-
nologies are being harnessed for this purpose. The first of these
is expression microarray analysis, which has the potential to
identify gene expression patterns in diagnostic specimens that
portend a high probability of relapse (Ferrando et al., 2002;Yeoh
et al., 2002). Distinguishing patients who are likely to relapse is
confounded by the fact that specific leukemia-associated fusion
genes such as TEL-AML1 and E2A-PBX have global effects on
gene expression that must first be accounted for when consider-
ing relapse risk. However, when subgroups of pediatric ALL
specimens with the same chromosomal translocations were
examined, it was possible to identify groups of genes whose
expression correlated with later disease relapse (Yeoh et al.,
2002). Additional data are essential to confirm these preliminary
findings in both pediatric and adult patients, and to decipher the
influence of different treatment regimens on the predictive value
of gene expression patterns. A number of groups are exploring
either flow cytometry or polymerase chain reaction (PCR)-based
strategies to detect rare residual leukemia cells in patients that
are in morphologic remission. Recent studies in pediatric ALL
have established that detecting certain levels of residual
leukemia early in therapy correlated with a high risk of relapse
(Coustan-Smith et al., 2002; Cave et al., 1998; Gaynon et al.,
1997). An important question for clinical investigation involves
whether intensifying therapy in ALL patients who are in morpho-
logic remission but have high levels of minimal residual disease
will alter the outcome of the disease. Several ongoing clinical tri-
als are beginning to prospectively address this issue. By con-
trast, gene expression and minimal residual disease techniques
might ultimately allow clinical oncologists to reduce the doses of
mutagenic drugs administered to patients with ALL that have
highly favorable biologic features.
Lastly, Imatinib, also known as STI-571 and Gleevec, is a
small molecule inhibitor of the BCR-ABL kinase that has
demonstrated impressive efficacy in patients with chronic myel-
ogenous leukemia (CML) (Druker, 2002; Druker et al., 2001).
Moreover, treatment with Imatinib induces transient remissions
in many CML patients with lymphoid blast crisis (Kantarjian et
al., 2002; Sawyers et al., 2002), and thus represents a promis-
ing approach for improving the outcome of adults and children
with BCR-ABL-positive ALL. However, the rapid emergence of
Imatinib resistant clones in BRC-ABL-positive ALL (Gorre et al.,
2001; Shah et al., 2002) suggests that effective use of this drug
in ALL will require its delivery in combination with other agents,
including possibly other BCR-ABL inhibitors that are directed to
a separate region of the ABL kinase.
The spectrum of acute myeloid leukemias and the
myelodysplastic syndromes
AML is defined as a clonal expansion of myeloid blasts that com-
prise ≥20% of the nucleated cells in the bone marrow or blood.
By contrast, MDS is defined as a clonal hematopoietic stem cell
disease that is characterized by dysplasia and ineffective
hematopoiesis in one or more of the myeloid lineages. Often the
dysplasia is accompanied by an increase in myeloblasts; howev-
er, these cells account for less than 20% of the total. From both a
biological and clinical perspective, AML and MDS are heteroge-
neous diseases, consisting of many recognized morphologic
and biological subtypes. A number of different classification
schemes have been proposed over the years to assist in accu-
rately diagnosing clinically relevant disease subtypes. One of the
most recent classifications is that sponsored by the World Health
Organization (WHO) (Vardiman et al., 2002). The relevant parts
of the WHO classification scheme that are germane to our dis-
cussion are shown in Table 2.
Although AML and MDS in their classic forms are easily dis-
tinguished from one another, the diseases can be conceptual-
ized to represent a continuum of pathogenic entities (Figure 2).
At one extreme sits the AMLs that arise without any evidence of
a preceding MDS and show minimal dysplasia outside of the
myeloid lineage. This subtype of AML is characterized by the
presence of recurrent chromosomal translocations or
rearrangements that encode chimeric oncoproteins, including
AML1-ETO, CBFβ-MYH11, PML-RARα, and MLL fusions. The
incidence of these specific leukemia subtypes is relatively con-
stant throughout life. At the other extreme sits the AMLs that
arise in patients with a preceding history of MDS. In fact, for
many subtypes of MDS, progression to AML is the natural
course of the disease. The incidence of both MDS and the
AMLs that arise in these patients increases linearly with age
with a mean age of onset >65. In between these two extremes
exists an overlapping spectrum of entities from AMLs that lack
either recurrent cytogenetic abnormalities or evidence of dys-
plasia to acute myeloid leukemias with multilineage dysplasia.
The latter subgroup, although lacking a preceding history of
MDS, closely resembles leukemias that arise in MDS patients,
including having the presence of complex cytogenetic abnor-
malities, such as −7/del(7q), −5/del(5q), +8, +21, and 3q26
abnormalities.
AMLs with recurrent cytogenetic abnormalities
The underlying pathology and clinical outcome of the AMLs with
Table 2. World Health Organization (WHO) classification
Acute myeloid leukemia (AML)
AML with recurrent cytogenetic abnormalities
AML with multilineage dysplasia
AML and MDS, therapy related
AML not otherwise categorized
Acute leukemia of ambiguous lineage
Myelodysplastic syndromes (MDS)
Refractory anemia
Refractory anemia with ringed sideroblasts
Refractory anemia with multilineage dysplasia
Refractory anemia with excess blasts




Atypical chronic myeloid leukemia
Juvenile myelomonocytic leukemia
Myelodysplastic/myeloproliferative unclassifiable
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recurrent cytogenetic abnormalities appear to be similar in pedi-
atric and adult patients. The chromosomal rearrangements that
define many of these leukemias encode chimeric transcription
factors that directly alter the normal repertoire of expressed
genes that regulate the formation, self-renewal, and differentia-
tion of hematopoietic stem cells and their progeny. Prominent
among these pathways are those controlled by the AML1/CBFβ
transcription factor complex (Speck and Gilliland, 2002; Lorsbach
and Downing, 2001), the HOX developmental proteins (Look,
1997), and the retinoic acid receptor (Grignani et al., 1994).
Experiments in strains of mice engineered to express the
CBFβ-MYH11 (Castilla et al., 1996, 1999), AML1-ETO (Yuan et
al., 2001; Higuchi et al., 2002), MLL-AF9 (Corral et al., 1996;
Dobson et al., 1999), and PML-RARα (He et al., 1997) fusion
genes in hematopoietic cells strongly support the idea that
these oncoproteins are insufficient to induce a full leukemic
phenotype. Instead, expression of these fusion proteins
appears to alter the growth and differentiation of HSC generat-
ing a “preleukemia” population of cells that are then susceptible
to the acquisition of cooperating mutations to induce AML. The
initial expression of the translocation-encoded fusion proteins
appears to provide only a minimal to modest growth advantage
that is not detectable clinically. Nevertheless, recent studies
have demonstrated that cells expressing translocation-encoded
chimeric transcripts can be detected in the normal bone mar-
rows of patients who are in long-term remission from their
leukemia (Miyamoto et al., 1996, 2000) and in neonatal blood
spots from some patients that eventually develop AML
(Mahmoud et al., 1995; Gale et al., 1997; Ford et al., 1998;
Wiemels et al., 2002).
The number and type of cooperating mutations may vary
significantly between individual subtypes of AML. In addition,
the exact nature of cooperating mutations that can act with the
translocation-encoded fusion proteins remains to be defined.
Moreover, whether the specific constellation of cooperating
mutations will differ between patients that respond to standard
therapy and are cured and those that eventually relapse
remains unknown. Recent insights into the nature of cooperat-
ing mutations have emerged from a number of lines of investi-
gation. Rare patients with CML have been identified that have
acquired chromosomal translocations including the t(8;21) and
t(3;21) prior to undergoing a blast transformation to AML
(Kojima et al., 1999; Gilliland et al., 1990). Similarly, a patient
with chronic myelomonocytic leukemia that expressed the
Figure 2. A conceptual model of the pathogenesis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and MDS-related AML
Hematopoietic stem cells (HSC) or committee progenitors are formed early in development and persist throughout life. These cells are likely to vary in their
biologic properties with age, and thus during ontogeny may also vary in their susceptibility to different oncogenic events. The acquisition of certain chro-
mosomal translocations or rearrangements results in the production of fusion oncoproteins that typically result in the enhanced self-renewal capacity of
HSC and their committed progenitors. The cells serve as a silent prelukemic population that can acquire other cooperating mutations leading to the for-
mation of an overt leukemic clone. Two examples of this subtype of leukemia are t(8;21)-containing AML with M2 morphology (AML-M2) and t(15;17)-con-
taining acute promyelocytic leukemia (APL). By contrast, myelodypslastic syndrome (MDS) is thought to arise through the acquisition of multiple mutations.
Once established, the myelodyplastic stem cell can continue to undergo additional genetic and epigenetic changes, which in a substantial percentage
of cases will lead to the development of overt AML. MDS-related AML can also occur without a preceding history of MDS. Shown are examples of the type
of cellular morphology seen in a case of MDS-related AML.
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t(5;12)-encoded TEL-PDGFRβ fusion protein acquired a t(8;21)
prior to progressing to AML (Golub et al., 1994). In each case,
AML appeared to develop as a result of the cooperation
between an activated tyrosine kinase and a translocation-
encoded chimeric transcription factor. More recently, activating
mutations in the FLT3 receptor tyrosine kinase, including inter-
nal duplications of the juxtamembrane regions and point muta-
tions within the kinase domain, have been identified in
approximately 25% of AMLs (Nakao et al., 1996; Yamamoto et
al., 2001). Similarly, a high frequency of activating mutations
have been detected in NRAS, KRAS, and C-KIT (Kiyoi et al.,
1999; Beghini et al., 2000), primarily in leukemias with alter-
ations of the AML1/CBFβ transcription complex (the so-called
core binding factor leukemias).
These observations suggest that alterations in tyrosine
kinase signaling pathways may be an obligate step in leuke-
mogensis. This, in turn, raises the more provocative possibility
that specific small molecule inhibitors against activated kinases
may prove to be valuable therapeutic modalities in all AML
patients. Bolstered by the clinical success of Imatinib in treating
CML, a number of inhibitors of the FLT-3 kinase have recently
been developed. In preclinical studies, these compounds appear
to specifically inhibit the growth of some leukemia cells that con-
tain activating mutations in this receptor kinase (Kelly et al.,
2002; Levis et al., 2002; Sawyers, 2002; Weisberg et al., 2002).
Additional examples of directed therapy that are being pursued
in this subclass of AMLs are the use of all trans retinoic acid and
arsenic trioxide to treat acute promyelocytic leukemias (APL)
that express a PML-RARα fusion protein or its variants and the
use of histone deacetlylase inhibitors to treat a broader spec-
trum of AMLs. These topics have been recently reviewed by oth-
ers (Ferrara et al., 2001; Marks et al., 2001; Fenaux et al., 2001).
MDS and MDS-related AMLs: Lessons learned from the
pediatric diseases
MDS and MDS-related AML are relatively rare diseases in the
pediatric population, but are much more common in adults.
Moreover, as a group they respond very poorly to contemporary
treatment, with 5 year overall survival rates for the so-called
high-risk MDS-related AML falling below 10% (Oosterveld et al.,
2002). Hampering progress in treating MDS and MDS-related
AML is our relatively limited understanding of the molecular
pathology that underlies these diseases. Although commonly
deleted DNA segments have been identified on 5q31 and 7q22
that likely harbor myeloid tumor suppressors (Kratz et al., 2001;
Lai et al., 2001), the target gene(s) of the −7/del(7q) and 
−5/del(5q) remain unknown. Similarly, the genes that are critical
for the biological effects resulting from specific chromosomal tri-
somies remain to be identified. Can any insights be gained from
the analysis of those rare cases of MDS and MDS-related AML
that arise in children and adolescents?
Although MDS is uncommon in the pediatric age group, the
majority of cases share clinical, laboratory, and morphologic
features with one of the recognized subtypes of adult MDS and
are readily classified into one of the defined categories (Table
2). Pediatric patients with this “adult type” MDS are typically
older at diagnosis (>5 years old) (Luna-Fineman et al., 1999).
The remaining children with MDS demonstrate a mixed pattern
of myeloproliferation, dysplasia, and hepatosplenomegaly in
association with abnormal peripheral blood counts (most
frequently leukocytosis, anemia, and thombocytopenia).
Cytogenetic analysis reveals monosomy 7 in about 25% of
patients. These disorders have historically been called “juvenile
chronic myelogenous leukemia,” “infantile monosomy 7 syn-
drome,” and “chronic myelomoncytic leukemia” by different
authors (Luna-Fineman et al., 1995, 1999). In the 1990s, an
international working group proposed that the term “juvenile
myelomonocytic leukemia” (JMML) be applied to cases that ful-
fill a defined set of clinical and laboratory criteria. This nomen-
clature has been adopted widely, and JMML has been assigned
to a new diagnostic category with chronic myelomoncytic
leukemia (CMML) within the new WHO classification (Table 2).
A distinctive biologic feature of JMML is a selective hypersensi-
tive pattern of colony forming unit granulocyte macrophage
(CFU-GM) growth in response to the cytokine granulocyte-
macrophage colony stimulating factor (GM-CSF) (Emanuel et
al., 1991).
Approximately 30% of children with MDS or MDS-related
AML have a recognizable genetic predisposition to leukemia
such as neurofibromatosis 1 (NF1), Fanconi Anemia, or severe
congenital neutropenia. These associations may provide a
starting point for elucidating genes and growth control pathways
that may be critical in adult MDS and MDS-related AML.
JMML, NF1, and hyperactive Ras
Children (but not adults) with NF1 show a 200- to 500-fold
increase in the incidence of myeloid malignancies, particularly
JMML (Stiller et al., 1994). The NF1 gene encodes neurofi-
bromin, a GTPase-activating protein (GAP) that negatively reg-
ulates Ras output by accelerating GTP hydrolysis on Ras
(Boguski and McCormick, 1993; Donovan et al., 2002). Genetic
and biochemical analysis has shown that NF1 and its murine
homolog (Nf1) function as tumor suppressor genes in myeloid
leukemogenesis by negatively regulating Ras signaling (Bollag
et al., 1996; Jacks et al., 1994; Side et al., 1997). Furthermore,
identification of oncogenic RAS mutations in a substantial per-
centage of JMML samples from children without NF1 disease
further implicates hyperactive Ras in this disease (Kalra et al.,
1994). Although homozygous inactivation of Nf1 is lethal in
embryonic life, adoptive transfer of these mutant cells consis-
tently induces a JMML-like disorder in irradiated recipient mice
(Largaespada et al., 1996). Further studies in which fetal liver
cells doubly mutant at the Gmcsf and Nf1 loci were transferred
into irradiated Gmcsf−/− or wild-type recipients have under-
scored the central role of aberrant GM-CSF signaling in initiat-
ing and maintaining this myeloid leukemia in vivo (Birnbaum et
al., 2000). Together, these studies of children with JMML and of
Nf1 mutant mice have contributed novel insights regarding how
aberrant Ras signaling and hematopoietic growth factors coop-
erate to initiate and maintain leukemogenesis.
Fanconi anemia (FA)
FA is an autosomal recessive disorder characterized by multiple
congenital anomalies and progressive bone marrow failure, and
is associated with a high frequency of MDS and AML in late
childhood and adolescence. A hallmark of FA cells is hypersensi-
tivity to genetic damage induced by DNA-crosslinking agents
such as mitomycin C, and to a lesser extent by ionizing radiation.
FA is a heterogeneous disease at the molecular level with seven
distinct complementation groups identified. The genes for six of
these complementation groups have been recently cloned,
resulting in the emergence of a fascinating story on the interac-
tion of the different FA proteins in a DNA repair pathway
(Taniguchi and Dandrea, 2002; Stewart and Elledge, 2002). DNA
damage activates the FA complex (consisting of Fanconi pro-
teins A, C, G, and F), leading to the monoubiquitination of the
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FANCD2 protein (Garcia-Higuera et al., 2001). The modified
FANCD2 protein, in turn, relocalizes in the nucleus to sites of
DNA repair where it directly interacts with the breast cancer sus-
ceptibility protein, BRCA1. Furthermore, the FNCD2 protein is
phosphorylated by the ATM protein kinase in response to ioniz-
ing radiation, linking the Fanconi pathway to this checkpoint
response (Taniguchi et al., 2002). Lastly, mutations in the
BRCA2 gene, a DNA repair enzyme, were shown to be the
underlying abnormality in FA patients that were previously
assigned to complementation group B and D1 (Howlett et al.,
2002).These data establish a defect in DNA repair as the under-
lying abnormality in FA. Determining why FA patients primarily
develop AML is an important experimental priority. Moreover,
since MDS and AML in FA patients resemble the sporadic forms
of these diseases, it will be important to ascertain if acquired
mutations in components of the FA pathway are involved in the
pathogenesis of these myeloid malignancies in adults.
Congenital neutropenia
Severe congenital neutropenia (SCN) refers to a group of con-
stitutional disorders of myelopoiesis characterized by low blood
neutrophil counts and recurrent infections (Zeidler and Welte,
2002). Pharmacologic doses of recombinant human granulo-
cyte colony stimulating factor (G-GSF) enhance neutrophil pro-
duction in most patients, and this alleviates many of the
life-threatening complications of SCN. With longer survival and
close observation, evolution to MDS and AML has been
observed in 10%–15% of children with SCN, including occa-
sional patients who never received recombinant G-CSF
(Banerjee and Shannon, 2001). Clonal evolution is associated
with RAS mutations and monosomy 7 in some patients (Kalra et
al., 1995); however, the most fascinating molecular alteration is
the acquisition of somatic mutations in the G-CSF receptor,
which truncate the carboxyl terminus. Heterologous expression
of these mutant receptors in myeloid cell lines promotes growth,
blocks maturation, and impairs apoptosis (Dong et al., 1995).
However, studies in transgenic mice suggest that mutations in
the G-CSF receptor are insufficient to initiate leukemogenesis.
Recently, mutations in the neutrophil elastase (ELA2) gene
have been implicated as a cause of SCN (Ancliff et al., 2001).
SCN thus provides another example in which an inherited pre-
disposition interacts with a growth factor receptor-signaling cas-
cade in leukemogenesis.
Down syndrome (DS)
Infants and children with DS have a 14-fold increase in the over-
all rate of leukemia (Arceci, 2002). Although ALL is more preva-
lent than AML, the ratio of lymphoid to myeloid leukemia is
about 6:4 versus 4:1 in the general population. In addition, some
infants with DS develop clinical features of AML that resolve
spontaneously over time, which is referred to as transient
myeloproliferative disease (TMD). This term is misleading as
TMD does not resolve in some infants, while others go on to
develop AML after a period of remission. Cases of AML in
patients with DS frequently are classified as megakaryoblastic
(M7). Recently, somatic mutations were identified in the tran-
scription factor GATA1 in leukemias from children with DS
(Wechsler et al., 2002). It will be of interest to ascertain if these
mutations are invariably associated with leukemia or are also
found in some infants with TMD. Furthermore, DS provides a
novel opportunity to begin to address how an extra copy of a
critical gene (or genes) located on chromosome 21 interacts
with other events to promote leukemogenesis.
Although our understanding of the pathogenesis of MDS
and MDS-related AML remains in its infancy, some of the
recently acquired insights gained from studies of both the pedi-
atric and adult diseases are starting to translate into novel ther-
apeutic approaches. The prominent role of RAS alterations in
both congenital and sporadic cases of MDS and MDS-related
AML suggest that inhibitors against this pathway may be of ben-
efit. Recently, a specific inhibitor of the Ras processing enzyme
farnesyl transferase has been tested in a murine model of
JMML characterized by hyperactive Ras (Mahgoub et al.,
1999). Whether this will prove beneficial in treating patients with
these diseases remains to be determined. Other recent findings
are likely to influence the therapeutic approaches that will be
used to treat these diseases. Prominent among these observa-
tions is the finding of an increased frequency of MDS and MDS-
related AMLs in patients with congenital syndromes that render
them hypersensitive to DNA damage. Accumulating data from
both congenital and acquired cases of MDS-related AML raises
the possibility that these diseases have as part of their underly-
ing pathogenesis an enhanced mutation rate secondary to
alterations in normal DNA damage response pathways. If this is
true, we will need to take this possibility into account when
devising therapeutic strategies.
Conclusions
The insights gained through the coordinated efforts to study the
biology and therapy of pediatric ALL, AML, and inherited syn-
dromes that predispose to these diseases are providing impor-
tant insights in the underlying biology of these malignancies in
both pediatric and adult patients. Moreover, this information is
starting to influence the way patients are treated. In their accom-
panying focus article on embryonal malignancies, Maris and
Denny emphasize the interrelationship between developmental
processes and childhood cancer (Maris and Denny, 2002 [this
issue of Cancer Cell]). As described above, this comparison
extends to the pediatric leukemias. The point-counterpoint com-
parisons between pediatric and adult leukemias should continue
to provide fertile ground upon which we can expand our under-
standing of the molecular pathology of these cancers.
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